Psoriasis
Explore original articles, case reports, and podcasts that focus on psoriasis.
Importance of Complete Skin Clearance in Psoriasis as a Treatment Goal: Implications for Patient-Reported Outcomes
May 2020 | Volume 19 | Issue 5 | Original Article | 487 | Copyright © May 2020
Psoriasis is associated with physical, psychological, social, and economic burdens that lead to substantial impairment over a patient&rsqu...
Read MoreTreatment of Plaque Psoriasis With an Excimer Laser Utilizing an Optimal Therapeutic UVB Dose Protocol
April 2020 | Volume 19 | Issue 4 | Original Article | 349 | Copyright © April 2020
Background: Traditionally, treatment with the excimer laser requires determining the minimal erythema dose on healthy skin or using plaque-based induration; however, these protocols o...
Read MoreHalobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities
April 2020 | Volume 19 | Issue 4 | Original Article | 389 | Copyright © April 2020
Background: Plaque psoriasis can occur in all body regions, with the trunk and extremities among the most commonly affected areas. A fixed combination halobetasol propionate 0.01%/taz...
Read MoreEvaluation of Patient-Reported Outcomes with Etanercept in Moderate to Severe Plaque Psoriasis Patients After Therapy With Apremilast
April 2020 | Volume 19 | Issue 4 | Original Article | 378 | Copyright © April 2020
Background: Patients with moderate-to-severe psoriasis can have symptoms resulting in significant impact on patient-reported outcomes (PROs). The effect of etanercept (ETN) in moderat...
Read MoreTumor Necrosis Factor Inhibitor-Induced Psoriasis in a Pediatric Crohn’s Disease Patient Successfully Treated with Ustekinumab
March 2020 | Volume 19 | Issue 3 | Case Reports | 328 | Copyright © March 2020
Background: Tumor necrosis factor (TNF) inhibitors are widely used in pediatric patients with inflammatory bowel disease, as well as psoriasis. However, there is growing evidence that...
Read MoreEfficacy and Safety of Systemic Treatments for Skin and Joint Manifestations in Patients With Psoriasis
March 2020 | Volume 19 | Issue 3 | Original Article | 306 | Copyright © March 2020
Psoriasis is a chronic, systemic disease with features suggestive of autoimmune dysregulation. Patients with psoriasis vulgaris frequently experience systemic comorbidities, including cardiovascular a...
Read MoreManagement of Residual Psoriasis in Patients on Biologic Treatment
February 2020 | Volume 19 | Issue 2 | Original Article | 188 | Copyright © February 2020
While biologics are highly effective, most psoriasis patients do not achieve...
Read MoreClinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis
February 2020 | Volume 19 | Issue 2 | Original Article | 138 | Copyright © February 2020
The interleukin-17 (IL-17) pathway plays a crucial role in the development of psoriasis. Briefly, naive T cells differentiate into helper ...
Read MoreRandomized, Investigator-Blinded Study to Compare the Efficacy and Tolerance of a 650-microsecond, 1064-nm YAG Laser to a 308-nm Excimer Laser for the Treatment of Mild to Moderate Psoriasis Vulgaris
February 2020 | Volume 19 | Issue 2 | Original Article | 176 | Copyright © February 2020
BACKGROUND: Phototherapy is a safe and effective modality for the treatment of mild to moderate psoriasis.
OBJECTIVES: To compare the efficacy and safety of the 650-microsecond, 1064-nm pu...
Read MoreRapid and Sustained Improvement in a Patient With Plaque Psoriasis Switched to Brodalumab After Failing Treatment Clearance on Six Other Biologic Therapies
January 2020 | Volume 19 | Issue 1 | Case Reports | 86 | Copyright © January 2020
Psoriasis is a chronic, inflammatory, remitting/relapsing autoimmune condition involving a dysregulated inflammatory response of the interleukin (IL) 23/T-helper (Th)-17 pathway. Greater understanding...
Read MoreTreatment of Recalcitrant Acrodermatitis Continua of Hallopeau With Brodalumab
October 2019 | Volume 18 | Issue 10 | Editorials | 1047 | Copyright © October 2019
Acrodermatitis continua of Hallopeau (ACH) is a relatively rare chronic disorder with clinical findings of pustules and erythematous plaques on the digits.1 Although it is a variant of pustular psoria...
Read MoreThe Paradoxical Induction of Crohn’s Disease Following Treatment of Psoriatic Arthritis With Etanercept
August 2019 | Volume 18 | Issue 8 | Case Reports | 832 | Copyright © August 2019
Introduction: While psoriasis, psoriatic arthritis, and Crohn’s Disease (CD) all share a common central pathogenesis pathway and a wide overlap of treatment regime, discrepancie...
Read MoreResolution of Guttate Psoriasis Plaques After One-time Administration of Guselkumab
August 2019 | Volume 18 | Issue 8 | Case Reports | 822 | Copyright © August 2019
Guttate psoriasis is an acute subtype of plaque psoriasis characterized by eruption of small, scaly plaques, and papules, 5 to 10 mm in size over the trunk and proximal extremities.1 It oft...
Read MoreHalobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
August 2019 | Volume 18 | Issue 8 | Original Article | 815 | Copyright © August 2019
Background: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Topical corticosteroids (TCS) are the mainstay of treatment. Long-term safet...
Read MoreEfficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials
August 2019 | Volume 18 | Issue 8 | Original Article | 804 | Copyright © August 2019
Dupilumab, a monoclonal antibody that blocks the shared receptor subunit for interleukin (IL)-4 and IL-13, is currently approved for the treatment of adults with inadequately controlled moderate-to-se...
Read MoreUse of In-Office Preparations by Dermatologists for the Diagnosis of Cutaneous Fungal Infections
August 2019 | Volume 18 | Issue 8 | Original Article | 798 | Copyright © August 2019
Cutaneous fungal infections account for millions of office visits per year, yet their varied presentations often lead to misdiagnosis. If dermatology clinics are Clinical Laboratory Improvement Amendm...
Read MoreTwo Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis
August 2019 | Volume 18 | Issue 8 | Original Article | 790 | Copyright © August 2019
Background: A novel foam formulation of halobetasol propionate, 0.05% (HBP-Foam) has been developed to treat plaque psoriasis in patients who prefer a thermostable topical foam with l...
Read MoreComparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis
August 2019 | Volume 18 | Issue 8 | Original Article | 776 | Copyright © August 2019
Psoriasis (PsO) is a common, systemic, chronic inflammatory disease characterized by key clinical symptoms, including itching, pain, and scaling, and is associated with substantial physical, psychosoc...
Read MoreA Review of Topical Corticosteroid Foams
August 2019 | Volume 18 | Issue 8 | Original Article | 756 | Copyright © August 2019
Background: Topical corticosteroids are efficacious treatment options for multiple dermatoses. However, ointments and cream corticosteroid vehicles can be cumbersome to patients and m...
Read MorePrescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database
August 2019 | Volume 18 | Issue 8 | Original Article | 745 | Copyright © August 2019
Introduction: Selecting a systemic therapy for patients with psoriasis is a complex process, based on a variety of factors including psoriasis severity, comorbid health conditions, ac...
Read More